Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA 2623458 A1 · Owner: Holmes, Darren L. · Inventors: Ezrin, Alan M.; Bridon, Dominique P.; Milner, Peter G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for protecting a peptide from peptidase activity in vivo the , peptide being composed of between 2 and 50 amino acids and having a Cterminus and an N-terminus and a C-terminus amino acid and an Nterminus amino acid is described. In the first step of the method the , peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the Cterminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 17, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 17, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 17, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.